MINT-CELECOXIB CAPSULE

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CELECOXIB

Disponibbli minn:

MINT PHARMACEUTICALS INC

Kodiċi ATC:

M01AH01

INN (Isem Internazzjonali):

CELECOXIB

Dożaġġ:

100MG

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

CELECOXIB 100MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30/1000

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

CYCLOOXYGENASE-2 (COX-2) INHIBITORS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0137043001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2014-11-17

Karatteristiċi tal-prodott

_MINT-CELECOXIB (celecoxib) _
_Page 1 of 57 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-CELECOXIB
Celecoxib Capsules
Capsules, 100 mg and 200 mg, for oral use
Non-steroidal Anti-Inflammatory Drug (NSAID)
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Initial Authorization:
November 17, 2014
Date of Revision:
September 23, 2022
Submission Control No: 263511
_MINT-CELECOXIB (celecoxib) _
_Page 2 of 57 _
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
09/2022
7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests, Pregnancy
09/2022
7 WARNINGS AND PRECAUTIONS, Skin, _Serious skin reactions_
09/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant women
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED .
RECENT MAJOR LABEL CHANGES
......................................................................................................2
TABLE OF CONTENTS
........................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................................4
1
INDICATIONS
........................................................................................................................4
1.1
Pediatrics
.....................................................................................................................4
1.2
Geriatrics
.....................................................................................................................4
2
CONTRAINDICATIONS
...........................................................................................................5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
......................................................................6
4
DOSAGE AND ADMINISTRATION
...........................................................................................7
4.1
Dosing Considerations
...........